New dual-target CAR-T therapy takes on hard-to-treat blood cancers
NCT ID NCT06986434
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new treatment called CAR19-BCMA CAR-T for people with certain blood cancers (plasma cell neoplasms or lymphomas/leukemias) that have returned or not responded to at least three prior treatments. The therapy uses a patient's own immune cells, modified to target two markers (CD19 and BCMA) on cancer cells. The main goals are to check safety and find the best dose, with 20 participants enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMAS/LEUKEMIAS WITH PLASMACYTIC DIFFERENTIATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
the Fifth Medical Center of Chinese People's Liberation Army General Hospital
Beijing, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Engineered immune cells take aim at Hard-to-Treat myeloma
- Can engineered immune cells outsmart Treatment-Resistant myeloma?
- Can a lower dose of a myeloma drug keep the disease in check with fewer side effects?
- A pre-treatment pill may supercharge cancer-fighting immune cells
- Real-world data on multiple myeloma immunotherapies could reshape monitoring and improve survival
- New antibody combo aims to stall multiple Myeloma's return